KLK3 (7.23 fold change): Kallikrein 3, also known as prostatic specific antigen (PSA), has been used traditionally as a biomarker for the diagnosis and monitoring of PCa [18]. This evidence concerns the gene KLK3 and posterior cortical atrophy.